Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TCR2 THERAPEUTICS INC.

(TCRR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

TCR2 Therapeutics Inc. Reviews Pipeline and Strategy At R&D Day

10/20/2021 | 06:45am EST

TCR2Therapeutics Inc. unveiled new programs and provided highlights from its emerging TRuC pipeline programs during its first virtual R&D Day. Pipeline Updates: Gavo-cel: TCR2 announced the completion of the 3-patient cohort at the new dose level 3.5A (3x108/m2 following lymphodepletion) using a split dosing approach. Two patients were evaluable for safety. In both cases, gavo-cel was well-tolerated with no patients experiencing on-target, off tumors toxicities or Grade =3 cytokine release syndrome (CRS) non-hematologic toxicities. TCR2 anticipates the identification of the RP2D in 4Q21. TC-110: TCR2 announced that, in alignment with its pipeline prioritization on solid tumors, the Company has deprioritized the development of TC-110 for the treatment of patients with CD19+ non-Hodgkin lymphoma or adult acute lymphoblastic leukemia and plans instead to evaluate business development options. TC-510: TCR2 announced the Company anticipates the IND filing for its first TRuC-T cell enhanced with a PD1xCD28 switch receptor to be in 1Q22. TC-520: TCR2 announced the selection of its lead candidate targeting CD70 co-expressing an IL-15 enhancement as TC-520. In new preclinical data highlighted at the R&D Day, TC-520 enhanced with membrane-bound IL-15 resulted in a significant increase in TC-520 cells with a CD8+ na?ve/T memory stem cells phenotyope, improved autonomous persistence as well as increased expansion following repeated stimulation with CD70-expressing cancer cell lines. The Company anticipates initiating IND-enabling studies for TC-520 with an indication focus on renal cell carcinoma in 2022. Allogeneic: TCR2 announced new preclinical data demonstrating allogeneic (off-the-shelf) TRuC-T cells targeting mesothelin that utilized a CRISPR/Cas9 endonucleases approach and the use of fully human TCR?/d domains reduced the risk of immunogenicity and host rejection, lacked alloreactivity while maintaining clearance of tumor cells comparable to autologous TRuC-T cells targeting mesothelin. TCR2 is currently evaluating the combination of enhancements with allogeneic TRuC-T cells to potentially improve persistence. The Company anticipates the identification of a lead candidate for its allogeneic program in 2022. TRuC Tregs: TCR2 announced new preclinical data demonstrating proof-of-concept for TRuC Treg cells targeting HLA-A*02 for the prevention of Graft versus Host Disease (GvHD). in vitro and in vivo experiments, TRuC Tregs utilizing the full TCR signaling complex promoted and stabilized Tregs by suppressing the proliferation of mismatched effector cells and inhibiting the production of cytokines in a dose dependent manner. TCR2 plans to evaluate business development options to enable the treatment of patients with GvHD and other autoimmune diseases.


© S&P Capital IQ 2021
All news about TCR2 THERAPEUTICS INC.
11/22TCR2 Therapeutics Inc. Announces Resignation of Mayur Somaiya, Effective December 10, 2..
CI
11/11Tcr-2 therapeutics reports third quarter 2021 financial results and provides corporate ..
AQ
11/10TCR2 THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and..
AQ
11/10TCR2 Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate U..
PU
11/10TCR² Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate U..
AQ
11/10TCR2 Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months E..
CI
11/01TCR2 Therapeutics Announces Expansion of U.S. Manufacturing Capacity - Form 8-K
PU
11/01TCR2 THERAPEUTICS INC. : Costs Associated with Exit or Disposal Activities, Financial Stat..
AQ
11/01TCR² Therapeutics Announces Expansion of U.S. Manufacturing Capacity
AQ
11/01Tcr2 Therapeutics Inc. Announces Expansion of U.S. Manufacturing Capacity
CI
More news
Analyst Recommendations on TCR2 THERAPEUTICS INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -100,0 M - -
Net cash 2021 246 M - -
P/E ratio 2021 -1,95x
Yield 2021 -
Capitalization 197 M 197 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 164
Free-Float 96,4%
Chart TCR2 THERAPEUTICS INC.
Duration : Period :
TCR2 Therapeutics Inc. Technical Analysis Chart | TCRR | US87808K1060 | MarketScreener
Technical analysis trends TCR2 THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 5,15 $
Average target price 24,90 $
Spread / Average Target 383%
EPS Revisions
Managers and Directors
Garry E. Menzel President, Chief Executive Officer & Director
Mayur Ian Somaiya Chief Financial Officer
Ansbert K. Gadicke Chairman
Robert Hofmeister Chief Scientific Officer
Alfonso Quintás-Cardama Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
TCR2 THERAPEUTICS INC.-83.35%195
MODERNA, INC.252.74%149 412
LONZA GROUP AG28.41%58 671
IQVIA HOLDINGS INC.48.85%50 948
SEAGEN INC.-5.61%30 228
CELLTRION, INC.-42.34%24 321